ProKidney, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dina Ramadane from Bank of America Securities reiterated a Sell rating on the stock and has a $1.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dina Ramadane has given his Sell rating due to a combination of factors that highlight a challenging risk‑reward profile for ProKidney at this stage. While the company reaffirmed progress in enrolling its Proact‑1 trial and confirmed sufficient cash runway into mid‑2027, the shift of the potential BLA filing to early 2028 underscores a long path to any commercialization and prolongs the period of clinical and regulatory uncertainty.
Ramadane also emphasizes that ProKidney’s investment case rests almost entirely on a single asset, REACT, which remains subject to significant trial risk despite supportive Phase 2 data and an assumed 40% probability of success. In addition, even if the pivotal study meets its eGFR slope endpoint in 2027, she sees the eventual addressable market as potentially limited unless the data prove highly compelling, leading her to maintain an Underperform rating and a $1 price objective below the current share price.
Ramadane covers the Healthcare sector, focusing on stocks such as Biohaven Ltd., Vera Therapeutics, and ProKidney. According to TipRanks, Ramadane has an average return of 0.7% and a 55.56% success rate on recommended stocks.